GlassScriptPhysician profile
Debra K Graetz
NPI 1104963115
$3,759.17
in general payments reported to CMS, 2019-2025
22 companies · $709 in 2025
The $709 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $319 · 2021: $640 · 2022: $332 · 2023: $348 · 2024: $642 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,638.47 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $835.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $712.86 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $561.73 | 2021-2025 | |
| Lilly USA, LLC | $256.73 | 2019-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $252.78 | 2020-2025 | |
| Si-Bone, INC. | $160.65 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $160.05 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $152.69 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $140.72 | 2022-2023 | |
| Amgen INC. | $124.01 | 2021-2024 | Prolia, Evenity |
| Sanofi Pasteur INC. | $59.83 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $57.83 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Sunovion Pharmaceuticals INC. | $51.99 | 2019 | |
| Corium, LLC | $44.90 | 2024-2025 | Azstarys |
| Alphatec Spine, INC | $38.46 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $32.60 | 2024-2025 | Cologuard Collection Kit |
| Indivior INC. | $23.39 | 2024 | Sublocade |
| Axsome Therapeutics, INC. | $22.76 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $20.25 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.02 | 2025 | Trintellix |
| Seqirus USA INC | $16.31 | 2025 | Flucelvax, Fluad |
| Kowa Pharmaceuticals America, INC. | $14.56 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Graetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.